Drug Trial Radar · NCT04784910
Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer
Last checked: Nov 19, 2026Latest source record: Jul 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
423
Actual
Start
May 21, 2021
Primary completion
Nov 27, 2023
Study completion Dec 11, 2023
Sponsor
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.Industry
- Sponsor type
- Industry
- First posted
- Mar 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study aims to demonstrate the preventive effect of DWP14012 20 mg for peptic ulcer is non-inferior to that of Lansoprazole 15 mg in terms of prevention of peptic ulcer and confirm the safety of DWP14012 20 mg.
Conditions
- Peptic Ulcer
Interventions
DWP14012 20mgDrug
DWP14012 20mg, tablet, orally, once daily for up to 24 weeks
Lansoprazole 15 mgDrug
Lansoprazole 15mg capsule, orally, once daily for up to 24 weeks
DWP14012 20mg placeboDrug
DWP14012 20mg placebo-matching tablet, orally, once daily for up to 24 weeks
Lansoprazole 15 mg placeboDrug
Lansoprazole 15mg placebo matching capsule, orally, once daily for up to 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects who develop peptic ulcer by Week 24 as assessed by investigatorTime frame: at 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Asan Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.